• SENSEX
    NIFTY 50
Business

USFDA issues 14 observations to Aurobindo Pharma's Pashamylaram facility; shares slump 9%

Updated : November 14, 2019 12:22 PM IST

US FDA issues a 'Form 483' with 14 observations to its Unit IV of Aurobindo Pharma
Unit IV is a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad

You May Also Like

Live TV
Advertisement